Meet our experts

We are drug hunters, protein engineers, and research scientists. Our teams work with partners to understand their broad program goals, develop full research plans, and carry out that research with the same dedication and commitment as would be carried out by their internal teams.

Mosaic’s drug hunters

Our senior scientists and leaders are industry veterans with decades of translational and therapeutic development experience. They’ve collectively advanced 10+ candidates into the clinic and supported numerous IND-enabling efforts across diverse modalities – bringing exceptional insight and rigor to every program.

Eric Furfine PhD

Chief Scientific Officer

Eric brings experience in leadership roles in biotechnology and pharmaceutical companies to the role of Chief Scientific Officer at Mosaic.

He is a visionary leader and drug hunter in the biotech and pharmaceutical industry. As CSO and President of R&D at Eleven Biotherapeutics, his leadership drove an IPO that financed Phase 3 clinical studies and a lucrative licensing deal on a second therapeutic asset. His building the Adnectin protein therapeutic discovery platform at Adnexus resulted in the acquisition of the company by BMS, where subsequently five adnectins were advanced into clinical studies. As VP Preclinical Development at Regeneron, he played pivotal roles in developing game-changing drugs, such as Eylea.

Eric received his PhD in Biochemistry from Brandeis University
Scott Glaser PhD

SVP, Biologics Discovery

Scott brings 30+ years of experience in biologic drug discovery to Mosaic’s partners.

Scott previously served as Director of Antibody Therapeutics for Novartis (GNF) where he led antibody discovery and platform development efforts. Scott also worked at Pfizer as Sr. Director/ Site Head of the San Diego Centers for Therapeutic Innovations where he built the discovery team and participated in implementing CTI’s model for academic-industry collaboration. Prior to Pfizer, Scott led Antibody Therapeutics at Biogen Idec.

Over his career Scott has contributed to over 50 discovery programs, with multiple molecules advancing into clinical development. He has also pioneered protein technologies, demonstrated by his co-inventorship of 23 issued US patents and multiple pending applications.
Alexei Kazantsev PhD

Sr. Director Protein Design and Engineering

Alexei leads the Protein Design and Engineering team as well as multiple parter programs

He is a gifted scientist with domain expertise spanning structural and chemical biology, protein engineering, and tissue engineering. At Mosaic Biosciences, he spearheaded efforts to optimize the pharmacokinetic properties and selectivity of therapeutic protein candidates and led the design and development of hydrogel matrices for drug delivery and tissue regeneration. Prior to joining Mosaic, he conducted structural biology research on RNA and proteins using X-ray crystallography and SAXS techniques. Alexei received his PhD in Biochemistry from Indiana University Bloomington.

Attempts to keep up with sons in climbing gym
Tracey Mullen

Chief Strategy Officer

Tracey Mullen brings extensive experience in both drug discovery and biopharma commercial development. Prior to joining Mosaic, Tracey served as Senior Vice President of Biopharma at Twist Biosciences, which she joined through the acquisition of Abveris in November of 2021. At Twist, Tracey managed the Biopharma Solutions business unit, which included the integrated legacy Twist Biopharma and Abveris teams. Prior to Twist, she served as CEO of Abveris, a company offering premium in vivo antibody drug discovery services. Tracey initially served as Abveris’ Chief Operating Officer where she managed operations and project development for both therapeutic and critical reagent in vivo antibody discovery campaigns. Before Abveris, she served on the antibody discovery team at Biogen where she helped implement the technology transfer of the Adimab yeast display platform for antibody discovery and engineering. Previously she worked for Abpro, a contract research organization specializing in in vivo antibody discovery.

Tracey received her B.S. in Chemical and Biological Engineering from the Massachusetts Institute of Technology and her Executive MBA from Quantic School of Business and Technology

Leadership team

Jean-Pierre Wery

Chief Executive Officer

Jean-Pierre (“JP”) Wery is a seasoned biotech executive with deep expertise spanning discovery, development, and strategic partnerships. Prior to joing Mosaic as the CEO, he held leadership roles at Eli Lilly, Vitae Pharmaceuticals, Monarch Life Sciences, Crown Bioscience, and Sidewinder Therapeutics.

A serial entrepreneur, JP co-founded Crown Bioscience with a group of close colleagues, building it into a global leader in preclinical oncology services. He later founded Sidewinder Therapeutics, where he served as CEO until April 2025, driving innovation in precision ADC therapeutics.

Throughout his career, JP has been recognized for his ability to launch and scale organizations, forge impactful collaborations, and deliver high-quality solutions that accelerate drug discovery.

JP received his PhD in Structural Biology from the University of Liege (Belgium).
Eric Furfine PhD

Chief Scientific Officer

Eric brings experience in leadership roles in biotechnology and pharmaceutical companies to the role of Chief Scientific Officer at Mosaic.

He is a visionary leader and drug hunter in the biotech and pharmaceutical industry. As CSO and President of R&D at Eleven Biotherapeutics, his leadership drove an IPO that financed Phase 3 clinical studies and a lucrative licensing deal on a second therapeutic asset. His building the Adnectin protein therapeutic discovery platform at Adnexus resulted in the acquisition of the company by BMS, where subsequently five adnectins were advanced into clinical studies. As VP Preclinical Development at Regeneron, he played pivotal roles in developing game-changing drugs, such as Eylea.

Eric received his PhD in Biochemistry from Brandeis University
Tracey Mullen

Chief Strategy Officer

Tracey Mullen brings extensive experience in both drug discovery and biopharma commercial development. Prior to joining Mosaic, Tracey served as Senior Vice President of Biopharma at Twist Biosciences, which she joined through the acquisition of Abveris in November of 2021. At Twist, Tracey managed the Biopharma Solutions business unit, which included the integrated legacy Twist Biopharma and Abveris teams. Prior to Twist, she served as CEO of Abveris, a company offering premium in vivo antibody drug discovery services. Tracey initially served as Abveris’ Chief Operating Officer where she managed operations and project development for both therapeutic and critical reagent in vivo antibody discovery campaigns. Before Abveris, she served on the antibody discovery team at Biogen where she helped implement the technology transfer of the Adimab yeast display platform for antibody discovery and engineering. Previously she worked for Abpro, a contract research organization specializing in in vivo antibody discovery.

Tracey received her B.S. in Chemical and Biological Engineering from the Massachusetts Institute of Technology and her Executive MBA from Quantic School of Business and Technology
Scott Glaser PhD

SVP, Biologics Discovery

Scott brings 30+ years of experience in biologic drug discovery to Mosaic’s partners.

Scott previously served as Director of Antibody Therapeutics for Novartis (GNF) where he led antibody discovery and platform development efforts. Scott also worked at Pfizer as Sr. Director/ Site Head of the San Diego Centers for Therapeutic Innovations where he built the discovery team and participated in implementing CTI’s model for academic-industry collaboration. Prior to Pfizer, Scott led Antibody Therapeutics at Biogen Idec.

Over his career Scott has contributed to over 50 discovery programs, with multiple molecules advancing into clinical development. He has also pioneered protein technologies, demonstrated by his co-inventorship of 23 issued US patents and multiple pending applications.
Maggie Allman BA, PHR

Head of People

Maggie ensures that Mosaic’s highly skilled scientific and business experts succeed both at work and beyond. Her primary goal is to help create a healthy environment in which each Mosaic member can thrive, leading in turn to a dynamic culture that supports clients and empowers employees.

In her 17+ years of HR/Talent Management across a variety of company types and sizes, Maggie has developed a deep expertise in what is needed to attract, develop, and retain top industry talent: The foundation of Mosaic’s business model. She is particularly skilled in building trust and partnerships across all organizational levels, enhancing leadership capabilities, and refining processes and programs to help elevate both employee experience and company performance. As a dedicated advocate for people, Maggie is passionate about building a diverse, inclusive, and highly-engaged workforce.
Stacy Capehart

Director Data Science / Head of Lab Operations

Stacy leads the Data Science Team as well as multiple partner programs

She has held roles of increasing responsibility since joining Mosaic Biosciences in 2019. As a Director at Mosaic Biosciences, Stacy has led several teams for projects involving protein engineering, expression, chemical modification, and characterization as well as bioassay development and external PK/PD studies. Prior to joining Mosaic, Stacy conducted integral research at Editas Medicine and Velocity Sciences. Stacy received her Ph.D. in chemistry from the University of California, Berkeley.

Mango edamame burrito enthusiast
Alexei Kazantsev PhD

Sr. Director Protein Design and Engineering

Alexei leads the Protein Design and Engineering team as well as multiple parter programs

He is a gifted scientist with domain expertise spanning structural and chemical biology, protein engineering, and tissue engineering. At Mosaic Biosciences, he spearheaded efforts to optimize the pharmacokinetic properties and selectivity of therapeutic protein candidates and led the design and development of hydrogel matrices for drug delivery and tissue regeneration. Prior to joining Mosaic, he conducted structural biology research on RNA and proteins using X-ray crystallography and SAXS techniques. Alexei received his PhD in Biochemistry from Indiana University Bloomington.

Attempts to keep up with sons in climbing gym
Marty Stanton

Founder

Marty is an accomplished innovator and leader in biotechnology: Marty founded Mosaic and served as the CEO and CESO of the company until September 2025. Prior to founding Mosaic, Marty’s inventive prowess in the CSO and COO roles at SomaLogic led to the invention of the groundbreaking SomaScan assay. As Co-founder and President of Dexela, he spearheaded the advancement of 3D breast imaging technology. Prior to that, as the founder and President of Archemix, Marty’s exceptional leadership skills enabled the successful fundraising of over $100 million for the development of aptamer therapeutics. Marty received his PhD in Biophysics from Brandeis University.

Marty wonders if it is still possible to learn to play the piano

Want to join an experienced team driving discovery?

Our team combines decades of experience and a track record of advancing therapies from concept to clinic, making it an exciting place to grow your career.

10+

Over 10 therapeutic candidates advanced into clinical trials and onto the market.

100+

Our drug hunters have over a century of combined experience.

∞

Countless IND-enabling efforts across multiple modalities.

View our careers

Speak to a scientist

Connect with our discovery experts to discuss your program and explore how Mosaic can help move your ideas forward.

Start the conversation